Faranak Rezaei1, Mehri Haeili2, Abbasali Imani Fooladi3, Mohammad Mehdi Feizabadi4. 1. Department of Microbiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran. 2. Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran. 3. Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. 4. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVES: Development of molecular techniques for rapid detection of drug resistant tuberculosis allows for the prompt initiation of appropriate anti-TB treatment. We aimed to assess high-resolution melting (HRM) analysis for the detection of rpsL, rrs and embB mutations to identify streptomycin and ethambutol resistance in Mycobacterium tuberculosis. MATERIAL AND METHODS: A total of 76 clinical isolates of M. tuberculosis including 25 SM-R, 21 EB-R and 30 drug susceptible - determined by the proportion method of drug susceptibility testing (DST) - were analyzed by HRM analysis, and the results were confirmed using DNA sequencing. RESULTS: The sensitivity and specificity of the HRMA compared to phenotypic DST were 88% and 100.0%, respectively for the detection of streptomycin resistance (SM-R), and 90.4% and 96.6%, respectively for ethambutol resistance (EB-R). Three SM-R and two EB-R isolates had no mutations in the studied regions of rpsL, rrs and embB genes determined by DNA sequencing and therefore were not identified as resistant by HRM assay. Interestingly, one phenotypic EM-S isolate was found by sequencing to have a mutation at codon 423 (Met->Ilu) of embB gene and was clustered as resistant by HRM as well. CONCLUSIONS: The sensitivity and specificity of HRM curve assay was consistent with DNA sequencing, which is the gold standard method for genotypic DST. This assay can be utilized as a screening method for detection of drug-resistant tuberculosis, offering the advantages of a high throughput, single step, cost effectiveness, and rapid work flow method.
OBJECTIVES: Development of molecular techniques for rapid detection of drug resistant tuberculosis allows for the prompt initiation of appropriate anti-TB treatment. We aimed to assess high-resolution melting (HRM) analysis for the detection of rpsL, rrs and embB mutations to identify streptomycin and ethambutol resistance in Mycobacterium tuberculosis. MATERIAL AND METHODS: A total of 76 clinical isolates of M. tuberculosis including 25 SM-R, 21 EB-R and 30 drug susceptible - determined by the proportion method of drug susceptibility testing (DST) - were analyzed by HRM analysis, and the results were confirmed using DNA sequencing. RESULTS: The sensitivity and specificity of the HRMA compared to phenotypic DST were 88% and 100.0%, respectively for the detection of streptomycin resistance (SM-R), and 90.4% and 96.6%, respectively for ethambutol resistance (EB-R). Three SM-R and two EB-R isolates had no mutations in the studied regions of rpsL, rrs and embB genes determined by DNA sequencing and therefore were not identified as resistant by HRM assay. Interestingly, one phenotypic EM-S isolate was found by sequencing to have a mutation at codon 423 (Met->Ilu) of embB gene and was clustered as resistant by HRM as well. CONCLUSIONS: The sensitivity and specificity of HRM curve assay was consistent with DNA sequencing, which is the gold standard method for genotypic DST. This assay can be utilized as a screening method for detection of drug-resistant tuberculosis, offering the advantages of a high throughput, single step, cost effectiveness, and rapid work flow method.
Authors: S Sreevatsan; K E Stockbauer; X Pan; B N Kreiswirth; S L Moghazeh; W R Jacobs; A Telenti; J M Musser Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191
Authors: A Telenti; W J Philipp; S Sreevatsan; C Bernasconi; K E Stockbauer; B Wieles; J M Musser; W R Jacobs Journal: Nat Med Date: 1997-05 Impact factor: 53.440
Authors: P Bifani; B Mathema; M Campo; S Moghazeh; B Nivin; E Shashkina; J Driscoll; S S Munsiff; R Frothingham; B N Kreiswirth Journal: Emerg Infect Dis Date: 2001 Sep-Oct Impact factor: 6.883
Authors: Michael Krypuy; Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Sarah J Hyland; Anna DeFazio; Stephen B Fox; James D Brenton; David D Bowtell; Alexander Dobrovic Journal: BMC Cancer Date: 2007-08-31 Impact factor: 4.430